China's Pharma Dark Horse Just Landed a $507M Deal—Sleep Disorder Play You Can't Ignore

Very Bullish · $002262.SZ

What Happened

Enhua Pharmaceutical signed an exclusive licensing agreement with Somnivera, Inc. for a novel sleep disorder drug, receiving $10.5 million upfront and up to $507 million in milestones, plus royalties and a 15% equity stake in Somnivera.

Bottom Line

Enhua's first BD deal marks a pivotal shift to global pricing for its CNS pipeline, unlocking significant upside potential.

Free preview — more China A-share & HK research · About Us · Legal & Privacy